Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs

Abstract

Our results showed there was a longer time to SP in the contemporary subjects given DMD. Our analyses suggested that this effect was not solely driven by the inclusion of benign cases, and it was at least partly due to the long-term immunomodulating therapy given.